Sosei Group (JP:4565) has released an update.
Nxera Pharma has received a $10 million milestone payment from AbbVie for their collaborative effort in targeting neurological diseases using Nxera’s NxWave™ platform. This is part of a larger agreement potentially worth over $1.2 billion which includes additional research, development, and commercial milestones, along with tiered royalties. Nxera Pharma, a biopharma company with a strong pipeline of over 30 programs, is harnessing GPCR-targeted structure-based drug discovery to address unmet medical needs.
For further insights into JP:4565 stock, check out TipRanks’ Stock Analysis page.
